Holen Sie sich die Stockscreener-App
4.085
0.12%
-0.005
Zentalis Pharmaceuticals Inc Aktie (ZNTL) Neueste Nachrichten
Zentalis Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(4) - marketscreener.com
Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
New Zentalis hire gets 26,000 stock options at $4.09 a share - Stock Titan
Zentalis Pharmaceuticals (ZNTL) price target increased by 19.05% to 5.83 - MSN
[ARS] Zentalis Pharmaceuticals, Inc. SEC Filing - Stock Titan
Zentalis (ZNTL) schedules 2026 virtual meeting on directors, auditor and executive pay - Stock Titan
ZNTL Technical Analysis | Trend, Signals & Chart Patterns | ZENTALIS PHARMACEUTICALS INC (NASDAQ:ZNTL) - ChartMill
Zentalis Pharmaceuticals (ZNTL) Price Target Decreased by 14.14% to 5.42 - MSN
Zentalis Pharmaceuticals Announces Abstract Acceptance at ASCO 2026 Featuring Azenosertib in Combination with Paclitaxel for Platinum-Resistant Ovarian Cancer - The Manila Times
Zentalis Pharmaceuticals Announces Abstract Acceptance at - GlobeNewswire
Ovarian cancer drug combo data lands June ASCO presentation - Stock Titan
Zentalis (ZNTL) Locks In Its Cancer Drug Dose; Jefferies Raises the Target - Insider Monkey
ZNTL: Zentalis Presents Promising Data on Azenosertib at AACR 20 - GuruFocus
Zentalis Surges 20% on WEE1 Inhibitor Dose Selection—But Is Aprea the Real Winner in This Space? - Barchart.com
Zentalis presents preclinical data on cancer drug azenosertib By Investing.com - Investing.com Canada
Zentalis Highlights New Azenosertib Data in Breast Cancer - TipRanks
Zentalis Pharmaceuticals Presents Promising Preclinical Data on Azenosertib in Triple-Negative Breast Cancer and Insights on Cyclin E1-Positive Ovarian Cancer at AACR 2026 - Quiver Quantitative
Zentalis Pharmaceuticals To Present Azenosertib Preclinical Data in Triple-Negative Breast Cancer and Real-World Analysis of Unmet Need in Cyclin E1-Positive Ovarian Cancer at AACR 2026 - ChartMill
Zentalis (Nasdaq: ZNTL) unveils azenosertib TNBC and Cyclin E1 ovarian cancer data at AACR 2026 - Stock Titan
Zentalis Pharmaceuticals Reports Full Year 2025 Financial Results and Operational Updates - ADVFN
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Average Rating of "Hold" from Brokerages - MarketBeat
A Look At Zentalis Pharmaceuticals (ZNTL) Valuation After Azenosertib Dose Selection Milestone - Yahoo Finance
Guggenheim Increases Zentalis Price Target, Sparking Investor Interest - timothysykes.com
Zentalis Stock Jumps as Guggenheim Lifts Price Target on Cancer Program Success - StocksToTrade
Zentalis Pharmaceuticals: Price Target Boost Sparks Speculative Momentum - timothysykes.com
Is Zentalis Pharmaceuticals (NASDAQ:ZNTL) In A Good Position To Deliver On Growth Plans? - Moomoo
What's Behind The Surge In Zentalis Stock? - Sahm
Jefferies raises Zentalis stock price target on ovarian cancer trial data - Investing.com Canada
This small-cap biotech stock just hit a near 22-month high – but this analyst still expects another 56% rally - MSN
What's behind the surge in Zentalis stock? - MSN
Today's Analyst Rating Update for ZNTL: Buy Rating Maintained wi - GuruFocus
Zentalis Pharmaceuticals (NASDAQ:ZNTL) Price Target Raised to $10.00 - MarketBeat
H.C. Wainwright reiterates Zentalis stock rating on pivotal dose selection By Investing.com - Investing.com Canada
Azenosertib Shows Promising Results in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer: Zentalis Advances Registration-Intent Trials - Minichart
Zentalis Pharmaceuticals Announces 400mg QD 5:2 Azenosertib Monotherapy as the Pivotal Study Dose in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer - Bitget
Zentalis Advances Azenosertib Dose in DENALI Phase 2 - TipRanks
Zentalis Selects 400mg QD 5:2 Azenosertib Dose for Pivotal Ovarian Cancer Study - National Today
Zentalis selects 400mg dose for ovarian cancer drug trial By Investing.com - Investing.com UK
Zentalis selects 400mg QD 5:2 as pivotal azenosertib dose; DENALI topline due YE2026 - TradingView
Azenosertib 400mg dose to anchor Zentalis (NASDAQ: ZNTL) late-stage ovarian cancer trials - Stock Titan
Zentalis Pharmaceuticals Announces 400mg QD 5:2 Azenosertib - GlobeNewswire
Is Zentalis Pharmaceuticals (ZNTL) Stock a Value Play | Price at $2.69, Up 2.28%Crowd Consensus Signals - Cổng thông tin điện tử tỉnh Lào Cai
ZNTL Should I Buy - Intellectia AI
Zentalis Pharmaceuticals PAO sells $7.8k in stock - Investing.com
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Zentalis Pharmaceuticals announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView — Track All Markets
Two new Zentalis hires get stock options priced at $2.57 - Stock Titan
ZNTL PE Ratio & Valuation, Is ZNTL Overvalued - Intellectia AI
0.83%
0.61%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):